Camptothecin is an analogue of the standard-of-care chemotherapeutic irinotecan used to treat colon cancer, and CHEK1 inhibitors can potentiate responses of DNA-damaging compounds through abrogation of DNA damage-induced cell cycle arrest20–22. Here, CHEK1 is linked to malignant colon neoplasm.